Heart failure & cardiomyopathiesCohort study
Biomarkers to Predict Abnormal Technetium-99m Pyrophosphate Scans in Patients With Suspected Transthyretin Amyloidosis
- Retrospective cohort study
Authors' conclusion
In patients undergoing 99mTc PYP imaging for suspected ATTR-CM, very low hs-cTnT levels can effectively rule out the diagnosis, although in a small subset of patients.
Study context
- Population
- Patients undergoing 99mTc PYP imaging for suspected ATTR-CM with ≥1 hs-cTnT measurement within 6 months of the scan, US, May 2013–September 2022
- Participants
- 50 / 1,378 / 45
- Exposure
- hs-cTnT and NT-proBNP thresholds for predicting abnormal 99mTc PYP scans
- hs-cTnTn = 50
- NT-proBNPn = 1,378
- hs-cTnT + NT-proBNPn = 45
- Outcome
- Predictive value of hs-cTnT and NT-proBNP for ATTR-CM
Main finding
As reported in the abstract
Ruling out ATTR-CM
| Group | Value | NPV | Sensitivity | Ruled out (without ATTR-CM) |
|---|---|---|---|---|
| hs-cTnT | 3.5% | 100% (95% CI: 93%-100%) | 100% (95% CI: 99%-100%) | |
| hs-cTnT + NT-proBNP | 3.3% | 45 (3.3%) |
Observational data: associations, not effects.
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Biomarkers to Predict Abnormal Technetium-99m Pyrophosphate Scans in Patients With Suspected Transthyretin Amyloidosis. JACC CardioOncol. Published 21 January 2025. doi:10.1016/j.jaccao.2024.10.013
Summarised from the published abstract; every number is checked against it